PET-CT

• ensures extremely short acquisition times;
• allows low-dose scans to be performed;
• offers the ability to perform imaging at half the PET dose (compared to the standard dose) and half the scanning time of traditional systems;
• detects the smallest lesions thanks to exceptional image quality.

The greater axial field of view coverage:

• provides coverage up to 26 cm;
• allows scanning in the fewest possible bed positions;
• ensures complete organ coverage and short acquisition times.

For the first time in PET reconstruction, it is not necessary to choose between excellent image quality and consistency of quantitative SUV measurements: this will make it possible to quickly determine the effectiveness of the treatment plan.

The PET-CT scanner allows studies of any body region to be performed using numerous radiopharmaceuticals. Currently, by far the most widely used radiopharmaceuticals are:

• he 18-Fluorodeoxyglucose, Fluorocholine and the’ F-DOPA that allow the study of glucose metabolism, which is typically increased in cancer cells.

Furthermore, for the prevention, diagnosis, and treatment of dementias (Alzheimer's), it is possible to study the distribution of the beta-amyloid protein in the brain using a new method (Amyloid PET).

Clear, the cutting-edge image reconstruction technology, enables fast and effective readings, ensuring greater safety when evaluating the patient's response to oncological treatment. It improves PET quantification accuracy and image quality by up to two times.

L’integrazione delle due tecnologie permette di ottenere una valutazione più completa, mettendo in relazione le informazioni sull’attività metabolica con la localizzazione anatomica delle aree esaminate.